Table 2.
Frequency and total number of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) at baseline, 1-month, and 1-year time points
| Frequency of CIPN-sxa | Baseline (pre-treatment) | One-month time pointb | One-year time pointc | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Ctx+ | Ctx− | Ctx+ | Ctx− | Ctx+ | Ctx− | ||||
| %a | %a | Significance | %a | %a | Significance | %a | %a | Significance | |
| Sensory symptoms | |||||||||
| Numbness/tingling in hands | 18.2 | 18.2 | 1.000e | 59.1 | 13.6 | 0.002 d | 63.6 | 13.6 | 0.001 d |
| Numbness/tingling in feet | 9.1 | 18.2 | 0.664e | 54.5 | 9.1 | 0.001 d | 57.1 | 18.2 | 0.008 d |
| Discomfort in hands | 13.6 | 22.7 | 0.698e | 54.5 | 18.2 | 0.012 d | 52.4 | 27.3 | 0.092 d |
| Discomfort in feet | 18.2 | 27.3 | 0.472d | 59.1 | 27.3 | 0.033 d | 59.1 | 45.5 | 0.365d |
| Motor symptoms | |||||||||
| Joint pain/muscle cramps | 50.0 | 50.0 | 1.000d | 68.2 | 72.7 | 0.741d | 72.7 | 71.4 | 0.924d |
| Feeling weak all over | 22.7 | 22.7 | 1.000d | 77.3 | 36.4 | 0.006 d | 59.1 | 22.7 | 0.014 d |
| Trouble walking | 18.2 | 36.4 | 0.176d | 36.4 | 54.5 | 0.226d | 38.1 | 59.1 | 0.169d |
| Auditory symptoms | |||||||||
| Trouble hearing | 18.2 | 40.9 | 0.099d | 27.3 | 45.5 | 0.210d | 27.3 | 54.5 | 0.066d |
| Ringing/buzzing in ears | 9.1 | 0.0 | 0.448e | 36.4 | 4.5 | 0.021 e | 33.3 | 4.5 | 0.046 e |
| Functional symptoms | |||||||||
| Trouble buttoning buttons | 9.1 | 0.0 | 0.448e | 31.8 | 0.0 | 0.009 e | 33.3 | 0.0 | 0.004 e |
| Trouble feeling the shape of small objects in hand | 9.1 | 27.7 | 0.412e | 54.5 | 31.8 | 0.128d | 31.8 | 27.3 | 0.741d |
| Total number of CIPN-sx | |||||||||
| Mean (SD) | 1.95 (2.4) | 2.59 (2.2) | 0.366f | 5.59 (3.5) | 3.14 (2.0) | 0.006 f | 5.18 (3.5) | 3.41 (2.3) | 0.049 f |
Note Values in italics are significant at α= 0.05
Ctx+ women with breast cancer treated with surgery and/or radiation and chemotherapy, Ctx− women with breast cancer treated with surgery and/or radiation but no chemotherapy, SD standard deviation
aFrequency is defined as the percentage of Ctx+ or Ctx− reporting this CIPN-sx in the last 7 days of this time point, regardless of severity
bOne month following chemotherapy completion or yoked interval for Ctx−
cOne year following 1-month time point
dDifferences between percentage of Ctx+ and Ctx− reporting individual CIPN-sx with adequate cell counts were tested using Pearson’s chi-squared tests, α = 0.05
eDifferences between nominal variables with inadequate cell counts (i.e., <5 observations) were tested with Fisher’s exact test (two-sided), α = 0.05
fDifferences in the total CIPN-sx reported by Ctx+ and Ctx− at each time point were tested using independent measured t test (α = 0.05)